Capricor Therapeutics
CAPR
17 hedge funds and large institutions have $279K invested in Capricor Therapeutics in 2019 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
6% more funds holding
Funds holding: 16 → 17 (+1)
0.33% less ownership
Funds ownership: 4.91% → 4.59% (-0.33%)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
89% less capital invested
Capital invested by funds: $2.44M → $279K (-$2.17M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$89.2K |
| 2 |
Two Sigma Investments
New York
|
+$83.9K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$23.5K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$21.5K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$10.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal London Asset Management
United Kingdom
|
-$1.98M |
| 2 |
IAA
Independent Advisor Alliance
Charlotte,
North Carolina
|
-$56K |
| 3 |
Morgan Stanley
New York
|
-$3.49K |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
-$2K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.07K |
CAPR Hedge Fund Activity: Q4 2019 in Review
17 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Capricor Therapeutics (CAPR) for Q4 2019, worth a combined $279K — down 89% from $2.44M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CAPR positions and 3 closed out — a net gain of 1 holder — while 3 added to existing stakes and 4 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $89.2K. The largest seller was Royal London Asset Management, exiting entirely with an estimated $1.98M sold.
- 17 institutional investors held Capricor Therapeutics (CAPR) as of Q4 2019, up from 16 in Q3 2019.
- Funds reported $279K of Capricor Therapeutics stock for Q4 2019, down 89% quarter-over-quarter.
- 4 funds opened new Capricor Therapeutics positions in Q4 2019 and 3 closed out, a net change of +1 holder.
- The largest Capricor Therapeutics buyer in Q4 2019 was Renaissance Technologies, an estimated $89.2K added.
- The largest Capricor Therapeutics seller in Q4 2019 was Royal London Asset Management, an estimated $1.98M sold.
Based on aggregated 13F filings for Q4 2019.